Special Issue

Animal Models for the Study of Human Diseases

Message from the Guest Editor

The use of animal models in biomedical research has been instrumental in advancing our understanding of human diseases. Animal models allow researchers to simulate the pathophysiology of human conditions, providing critical insights into disease mechanisms. therapeutic interventions, and drug efficacy. The translation of basic scientific knowledge into clinical applications often relies on these models, which provide important preclinical data to inform clinical trials and treatment strategies. This Special Issue, titled "Animal Models for the Study of Human Diseases", aims at showcasing the latest advancements in the use of animal models for understanding human diseases. improving therapeutic approaches, and bridging the gap between basic science and clinical practice. We invite high-quality research papers and reviews that highlight innovative techniques, findings, and applications in this ever-evolving field.

Guest Editor

Dr. Yong-He Ding

- 1. Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
- 2. The Biomedical Sciences Institute, Qingdao University, Qingdao 266073, China

Deadline for manuscript submissions

31 August 2025



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/228684

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).